Literature DB >> 24129826

Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.

Hop S Tran Cao1, Alpana Balachandran, Huamin Wang, Graciela M Nogueras-González, Christina E Bailey, Jeffrey E Lee, Peter W T Pisters, Douglas B Evans, Gauri Varadhachary, Christopher H Crane, Thomas A Aloia, Jean-Nicolas Vauthey, Jason B Fleming, Matthew H G Katz.   

Abstract

BACKGROUND: Venous resection may be required to achieve complete resection of pancreatic cancers. We assessed the ability of radiographic criteria to predict the need for superior mesenteric-portal vein (SMV-PV) resection and the presence of histologic vein invasion.
METHODS: All patients who underwent pancreaticoduodenectomy from 2004 to 2011 at the authors' institution were identified. Preoperative pancreatic protocol CT images were re-reviewed to characterize the extent of tumor-vein circumferential interface (TVI) as demonstrating no interface, ≤ 180° of vessel circumference, >180° of vessel circumference, or occlusion. Findings were correlated with the need for venous resection, histologic venous invasion, and survival.
RESULTS: A total of 254 patients underwent pancreaticoduodenectomy and met inclusion criteria; 98 (39.6 %) required SMV-PV resection. In our cohort, 76.4 % of patients received neoadjuvant chemoradiation. The TVI classification system predicted with fair accuracy both the need for SMV-PV resection at the time of surgery and histologic invasion of the vein. In particular, 89.5 % of patients with TVI > 180° or occlusion required SMV-PV resection. Of those, 82.4 % had documented histologic SMV-PV invasion. TVI ≤ 180° was associated with favorable overall survival compared to a greater circumferential interface.
CONCLUSIONS: A tomographic classification of the tumor-SMV-PV interface can predict the need for venous resection, pathologic venous involvement, and survival. To assist in treatment planning, a standardized assessment of this anatomic relationship should be routinely performed.

Entities:  

Mesh:

Year:  2013        PMID: 24129826      PMCID: PMC4016045          DOI: 10.1007/s11605-013-2374-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head.

Authors:  J H Allema; M E Reinders; T M van Gulik; D J van Leeuwen; L T de Wit; P C Verbeek; D J Gouma
Journal:  Br J Surg       Date:  1994-11       Impact factor: 6.939

3.  Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.

Authors:  D S Lu; H A Reber; R M Krasny; B M Kadell; J Sayre
Journal:  AJR Am J Roentgenol       Date:  1997-06       Impact factor: 3.959

4.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

5.  Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis.

Authors:  R J Bold; C Charnsangavej; K R Cleary; M Jennings; A Madray; S D Leach; J L Abbruzzese; P W Pisters; J E Lee; D B Evans
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

6.  The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery.

Authors:  V Raptopoulos; M L Steer; R G Sheiman; T G Vrachliotis; C A Gougoutas; J S Movson
Journal:  AJR Am J Roentgenol       Date:  1997-04       Impact factor: 3.959

7.  Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT.

Authors:  E M Loyer; C L David; R A Dubrow; D B Evans; C Charnsangavej
Journal:  Abdom Imaging       Date:  1996 May-Jun

Review 8.  Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Authors:  Gauri R Varadhachary; Eric P Tamm; James L Abbruzzese; Henry Q Xiong; Christopher H Crane; Huamin Wang; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Robert A Wolff
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

9.  Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?

Authors:  L E Harrison; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

10.  Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head.

Authors:  S D Leach; J E Lee; C Charnsangavej; K R Cleary; A M Lowy; C J Fenoglio; P W Pisters; D B Evans
Journal:  Br J Surg       Date:  1998-05       Impact factor: 6.939

View more
  23 in total

1.  An Untapped Resource: Left Renal Vein Interposition Graft for Portal Vein Reconstruction During Pancreaticoduodenectomy.

Authors:  Thuy B Tran; Matthew W Mell; George A Poultsides
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199

Review 2.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

Review 3.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.

Authors:  Laura Prakash; Priya Bhosale; Jordan Cloyd; Michael Kim; Nathan Parker; James Yao; Arvind Dasari; Daniel Halperin; Thomas Aloia; Jeffrey E Lee; Jean Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-09-15       Impact factor: 3.452

Review 5.  Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.

Authors:  R Álvarez; I Alés; R Díaz; B G de Paredes; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2017-06-13       Impact factor: 3.405

Review 6.  Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.

Authors:  Pierluigi di Sebastiano; Tommaso Grottola; F Francesco di Mola
Journal:  Updates Surg       Date:  2016-09-15

7.  Does Second Reader Opinion Affect Patient Management in Pancreatic Ductal Adenocarcinoma?

Authors:  Giuseppe Corrias; Sandra Huicochea Castellanos; Ryan Merkow; Russel Langan; Vinod Balachandran; Monica Ragucci; Gabriella Carollo; Marcello Mancini; Luca Saba; Lorenzo Mannelli
Journal:  Acad Radiol       Date:  2018-01-17       Impact factor: 3.173

8.  Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.

Authors:  Mohammed Aldakkak; Kathleen K Christians; Ashley N Krepline; Ben George; Paul S Ritch; Beth A Erickson; Fabian M Johnston; Douglas B Evans; Susan Tsai
Journal:  HPB (Oxford)       Date:  2015-08-10       Impact factor: 3.647

9.  Cold-stored cadaveric venous allograft for superior mesenteric/portal vein reconstruction during pancreatic surgery.

Authors:  Dyre Kleive; Audun E Berstad; Caroline S Verbeke; Sven P Haugvik; Ivar P Gladhaug; Pål-Dag Line; Knut J Labori
Journal:  HPB (Oxford)       Date:  2016-06-20       Impact factor: 3.647

10.  Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer.

Authors:  Hryhoriy Lapshyn; Peter Bronsert; Louisa Bolm; Martin Werner; Ulrich T Hopt; Frank Makowiec; Uwe A Wittel; Tobias Keck; Ulrich F Wellner; Dirk Bausch
Journal:  Langenbecks Arch Surg       Date:  2016-01-06       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.